✦ LIBER ✦

Are Patients with Inflammatory Bowel Disease Receiving Optimal Care?

✍ Scribed by Reddy, Sarathchandra I.; Friedman, Sonia; Telford, Jennifer J.; Strate, Lisa; Ookubo, Rie; Banks, Peter A.

Book ID: 126654671
Publisher: Nature Publishing Group
Year: 2005
Tongue: English
Weight: 89 KB
Volume: 100
Category: Article
ISSN: 0002-9270
DOI: 10.1111/j.1572-0241.2005.40849.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Care of Patients with Inflammatory Bowel

Care of Patients with Inflammatory Bowel Disease

✍ Kristina Amplo; Diane Nelson 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 356 KB

Do Inflammatory Bowel Disease patients w

Do Inflammatory Bowel Disease patients with anxiety and depressive symptoms receive the care they need?

✍ F. Bennebroek Evertsz'; N.A.M. Thijssens; P.C.F. Stokkers; M.A. Grootenhuis; C.L 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 295 KB

Outpatient health care utilization of pa

Outpatient health care utilization of patients with inflammatory bowel disease

✍ Marja J. Verhoef; Lloyd R. Sutherland 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 429 KB

Are Patients With Inflammatory Bowel Dis

Are Patients With Inflammatory Bowel Diseases at Increased Risk for Cardiovascular Disease?

✍ Theocharidou, Eleni; Gossios, Thomas D.; Karagiannis, Asterios 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Satisfaction of health care professional

Satisfaction of health care professionals managing patients with inflammatory bowel disease

✍ Casellas, Francesc; Ginard, Daniel; Vera, Isabel; Torrejón, Antonio 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 223 KB

Are accelerated infliximab infusions saf

Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?

✍ Shivaram Bhat; Divyesh Sharma; Pauline Doherty; Tony C.K. Tham; Grant R. Caddy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

Background: Infliximab is a monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). The manufacturerrecommended administration is over 2 hours followed by 2 hours of patient observation. The data relating to adverse outcomes in patients receiving accelerated infusions for IBD